Lucid Capital initiated coverage of Genelux (GNLX) with a Buy rating and $10 price target Genelux is a late clinical-stage biotechnology company focused on utilizing oncolytic viral immunotherapies for the treatment of cancer, the analyst tells investors in a research note. The firm sees a “low hanging fruit” opportunity for lead candidate Olvi-Vec in platinumresistant/refractory ovarian cancer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNLX: